<?xml version="1.0" encoding="UTF-8"?>
<p>The vast majority of safety issues were triggered by signals from post‐marketing experience and studies, while most of the quality and GMP non‐compliance issues originated from notifications of contamination and data integrity compromise. The identification of major flaws in bioequivalence studies
 <xref rid="pds5133-bib-0019" ref-type="ref">
  <sup>19</sup>
 </xref> or of systematic data manipulation in clinical trials
 <xref rid="pds5133-bib-0020" ref-type="ref">
  <sup>20</sup>
 </xref> triggered GCP non‐compliance issues. The only issue of supply shortage handled through the IRN was caused by fishing restrictions in Japan following a natural calamity in 2011, with consequent impaired sourcing of raw material for protamine sulphate.
 <xref rid="pds5133-bib-0021" ref-type="ref">
  <sup>21</sup>
 </xref>
</p>
